Market Structure 101 (ADMA)Just a quick video of me attempting to use market structure. Please let me what you think of my analysis.
ADMA Biologics Inc
No trades
No trades
Compare with ADMA Biologics Inc
0.72 USD
146.93 M USD
510.17 M USD
217.36 M
Last report date
Aug 5, 2026
Report period
Q2 2026
EPS
0.16 USD
Revenue
124.39 M USD
Earnings call summary
Q2 2026 saw strong ASCENIV growth, robust cash generation, and margin expansion, with ASCENIV revenue up 24% year-over-year and BIVIGAM stabilizing. Full-year guidance was reiterated, share repurchases continued, and SG-001 development advanced.
Details
Sector
Industry
CEO
Adam S. Grossman
Website
Headquarters
Ramsey
Founded
2004
IPO date
Oct 17, 2013
ISIN
US0008991046
CUSIP
000899104
FIGI
BBG002NCK5M5
Identifiers
ISIN US0008991046
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
ADMA Biologics Inc. (ADMA) Q4 2025 Earnings Call HighlightsADMA Biologics Inc. (NASDAQ: ADMA) delivered a robust financial performance in 2025, highlighted by significant year-over-year growth across key metrics. The company reported total revenue of $510 million for the full year, representing a 20% increase compared to the prior year. This top-line growth
Long
ADMAWhat is ADMA & its business profile
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics.
Yahoo Finance
+2
Admabiologics
+2
Its key products include BIVIGAM (an IVIG product for primary humoral immunodeficiency) and ASCENIV (ano
Long
Stock Of The Day / 05.08.25 / ADMA05.08.2025 / NASDAQ:ADMA
Fundamentals. Negative earnings report
Technical analysis.
Daily chart: Pullback on an uptrend. We mark the level of 18.80 formed by the trend break in April 2025.
Premarket: Gap Down on moderate volume.
Trading session: The downward movement from the opening
Long
ADMA Biologics, Inc. (ADMA) – Plasma Power with Policy TailwindsCompany Snapshot:
ADMA Biologics NASDAQ:ADMA is carving out a dominant position in plasma-derived immunotherapies, with a 100% U.S.-based supply chain that delivers both regulatory resilience and logistical strength in a vital healthcare segment.
Key Catalysts:
Strategic Domestic Advantage 🇺🇸
F
Long
$ADMA - Post-CorrectionIf you enjoy my analyses and want access to my indicators, consider following and supporting me.
After the correction that ended at the 1-Year Simple Moving Average support, the price made significant breakouts, indicating a possible resumption of the long-term uptrend.
Entry: 18.00
Technical Co
Long
ADMA – ADMA Biologics Inc. – 30-Min Bullish Breakout Setup!📈 🚀
🔹 Asset: ADMA (NASDAQ)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Trendline Support + Falling Wedge Breakout
📊 Trade Plan (Long Position)
✅ Entry Zone: Above $20.30 (breakout confirmation above wedge resistance)
✅ Stop-Loss (SL): Below $19.72 (below trendline and key structure)
🎯 Take Profit Tar
Long
ADMA (ADMA Biologics Inc.) – 30-Min Long Trade Setup! 🚀
🔹 Asset: ADMA – NASDAQ
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Bullish Breakout (Rising Wedge & Fibonacci Confluence)
📊 Trade Plan (Long Position)
✅ Entry Zone: Above $20.60 (Breakout Confirmation)
✅ Stop-Loss (SL): Below $19.75 (Key Support Level)
🎯 Take Profit Targets
📌 TP1: $21.68 (Resistanc
Long
New Setup: ADMAADMA: I have a swing trade setup signal. I'm looking to enter long if the stock can manage to CLOSE above the last candle high. If triggered, I will then place a stop-loss below (SL) and a price target above it(TP-50%,move SL to breakeven), then using the close below the 10SMA as my trailing stop lo
Long
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of ADMA is 9.90 USD — it has increased by 8.64% in the past 24 hours. Watch ADMA Biologics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ADMA Biologics Inc stocks are traded under the ticker ADMA.
ADMA stock has risen by 18.21% compared to the previous week, the month change is a 8.41% rise, over the last year ADMA Biologics Inc has showed a −37.54% decrease.
We've gathered analysts' opinions on ADMA Biologics Inc future price: according to them, ADMA price has a max estimate of 21.00 USD and a min estimate of 12.00 USD. Watch ADMA chart and read a more detailed ADMA Biologics Inc stock forecast: see what analysts think of ADMA Biologics Inc and suggest that you do with its stocks.
ADMA reached its all-time high on Apr 28, 2025 with the price of 25.67 USD, and its all-time low was 1.01 USD and was reached on Oct 21, 2021. View more price dynamics on ADMA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ADMA stock is 4.46% volatile and has beta coefficient of 1.15. Track ADMA Biologics Inc stock price on the chart and check out the list of the most volatile stocks — is ADMA Biologics Inc there?
Today ADMA Biologics Inc has the market capitalization of 2.25 B, it has increased by 4.89% over the last week.
Yes, you can track ADMA Biologics Inc financials in yearly and quarterly reports right on TradingView.
ADMA Biologics Inc is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
ADMA earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.16 USD resulting in a 0.98% surprise. The estimated earnings for the next quarter are 0.20 USD per share. See more details about ADMA Biologics Inc earnings.
ADMA Biologics Inc revenue for the last quarter amounts to 124.39 M USD, despite the estimated figure of 125.34 M USD. In the next quarter, revenue is expected to reach 138.12 M USD.
ADMA net income for the last quarter is 37.82 M USD, while the quarter before that showed 45.33 M USD of net income which accounts for 0.00% change. Track more ADMA Biologics Inc financial stats to get the full picture.
No, ADMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 8, 2026, the company has 647 employees. See our rating of the largest employees — is ADMA Biologics Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADMA Biologics Inc EBITDA is 224.19 M USD, and current EBITDA margin is 39.11%. See more stats in ADMA Biologics Inc financial statements.
Like other stocks, ADMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADMA Biologics Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADMA Biologics Inc technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADMA Biologics Inc stock shows the neutral signal. See more of ADMA Biologics Inc technicals for a more comprehensive analysis.